Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Finch Therapeutics Group Inc FNCH

Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U... see more

Recent & Breaking News (PINL:FNCH)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - FNCH

PR Newswire March 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - FNCH

Newsfile March 23, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - FNCH

Newsfile March 14, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - FNCH

PR Newswire March 9, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - FNCH

PR Newswire March 2, 2022

Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection

GlobeNewswire March 1, 2022

Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit

GlobeNewswire February 23, 2022

Finch Therapeutics Announces Additions to Senior Leadership Team

GlobeNewswire February 10, 2022

Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder

GlobeNewswire January 6, 2022

Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

GlobeNewswire January 4, 2022

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

GlobeNewswire December 20, 2021

Finch Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 11, 2021

Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

GlobeNewswire November 10, 2021

Finch Therapeutics Announces Transition of Chief Medical Officer

GlobeNewswire November 10, 2021

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

GlobeNewswire November 9, 2021

Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting

GlobeNewswire October 25, 2021

Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

GlobeNewswire October 12, 2021

Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors

GlobeNewswire October 5, 2021

Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer

GlobeNewswire September 8, 2021

Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021